Myelofibrosis surgery
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]Sabawoon Mirwais, M.B.B.S, M.D.[3]
Overview
Overview
Surgery is not the first-line treatment option for patients with myelofibrosis. Splenectomy is usually reserved for patients with massive splenomegaly unresponsive to conservative treatment. The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.
Surgery
Surgery
Splenectomy
- Surgery is not the first-line treatment option for patients with myelofibrosis.
- Splenectomy is usually reserved for patients with massive splenomegaly unresponsive to conservative treatment.[1][2][3]
- It is associated with postoperative morbidity rate of 15-30% and a mortality rate of 10%.
Allogeneic stem cell transplantation
The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.[4]
References
References
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Tefferi A (December 2018). “Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management”. Am. J. Hematol. 93 (12): 1551–1560. doi:10.1002/ajh.25230. PMID 30039550.
- ↑ Pardanani A, Tefferi A (August 2018). “How I treat myelofibrosis after failure of JAK inhibitors”. Blood. 132 (5): 492–500. doi:10.1182/blood-2018-02-785923. PMID 29866811.
- ↑ Cervantes F (2005). “Modern management of myelofibrosis”. Br. J. Haematol. 128 (5): 583–92. doi:10.1111/j.1365-2141.2004.05301.x. PMID 15725078. Unknown parameter
|month=ignored (help)
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH